A genetic variant within MDM4 3′UTR miRNA binding site is associated with HPV16‐positive tumors and survival of oropharyngeal cancer
- 12 September 2019
- journal article
- research article
- Published by Wiley in Molecular Carcinogenesis
- Vol. 58 (12) , 2276-2285
Abstract
As mouse double minute 4 (MDM4) and HPV16 E6 oncoproteins play important roles in inhibition of p53 activity, a functional polymorphism (rs4245739) in the 3′ untranslated regions of MDM4 targeted by microRNA‐191 may alter its expression level or functional efficiency, thus affecting tumor status and survival in human papillomavirus (HPV)‐positive squamous cell carcinoma of oropharynx (SCCOP). A total of 564 incident SCCOP patients with definitive radiotherapy were included for determination of tumor HPV16 status and genotypes of the polymorphism. Univariate and multivariable Cox models were performed to assess the associations between the polymorphism and outcomes. We found that MDM4 rs4245739 had statistically significant associations with tumor HPV‐positivity and survival of SCCOP patients. Patients with AC/CC variant genotypes of MDM4 rs4245739 were approximately 3‐fold more likely to be HPV16‐positive tumors among SCCOP patients compared with common homozygous AA genotype (adjusted odds ratio = 3.2, 95% confidence interval = 1.9‐5.5). Moreover, patients with MDM4 rs4245739 AC/CC variant genotypes had significantly better overall, disease‐specific, and disease‐free survival compared with those with the corresponding common homozygous AA genotype (all log‐rank = P < .05); and these genotypes were significantly associated with an approximately three to four times reduced risk of overall death, death owing to disease, and recurrence after multivariable adjustment. Finally, the significant effects of MDM4 rs4245739 polymorphism on survival were found among HPV16‐positive SCCOP patients only after the stratified analyses by tumor HPV status. We concluded that MDM4 rs4245739 polymorphism is significantly associated with tumor HPV status and survival of SCCOP, especially in HPV16‐positive SCCOP patients treated with definitive radiotherapy; nevertheless, prospective larger studies are warranted.Keywords
Funding Information
- National Institutes of Health (CA133099, CA186261‐01A1, R01 ES‐11740)
This publication has 61 references indexed in Scilit:
- Modifying effect of MDM4 variants on risk of HPV16‐associated squamous cell carcinoma of oropharynxCancer, 2011
- Polymorphisms of MDM4 and risk of squamous cell carcinoma of the head and neckPharmacogenetics and Genomics, 2011
- Single-Nucleotide Polymorphisms in p53 Pathway and Aggressiveness of Prostate Cancer in a Caucasian PopulationClinical Cancer Research, 2010
- Prognostic Significance of p16INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III TrialJournal of Clinical Oncology, 2010
- The p53 orchestra: Mdm2 and Mdmx set the toneTrends in Cell Biology, 2010
- Association of TGF-β1 Genetic Variants with HPV16-positive Oropharyngeal CancerClinical Cancer Research, 2010
- Association of p73 G4C14‐to‐A4T14 polymorphism with human papillomavirus type 16 status in squamous cell carcinoma of the head and neck in non‐Hispanic whitesCancer, 2009
- p73 G4C14‐to‐A4T14 polymorphism and risk of human papillomavirus‐associated squamous cell carcinoma of the oropharynx in never smokers and never drinkersCancer, 2008
- Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of HPV16-associated oral cancer in never-smokersCarcinogenesis, 2008
- Mdm2 and Mdm4 Loss Regulates Distinct p53 ActivitiesMolecular Cancer Research, 2008